Original Research
Published on 12 Dec 2022
First-in-human study to assess the safety, tolerability, pharmacokinetics and immunogenicity of DS002, an anti-nerve growth factor monoclonal antibody
in Drug Metabolism and Transport
- 7,709 views
- 3 citations